Middle East Healthcare Company
4009.SRSAUHealthcare● Active
$33.00
+$0.60(+1.85%)
Market Cap$3.0B
P/E Ratio—
52W High$60.7
52W Low$28.66
Middle East Healthcare Company (4009.SR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
4009.SR · earnings · updated Jun 15, 2026
Latest Earnings
Q2 FY2026Report Date: May 3, 2026EPS Actual
$0.28
Est. $0.80 · -64.9%
Revenue
$0.77B
Est. $0.77B · -0.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 3, 2026
After Market Close
▼ Miss EPS
4009.SR reports quarterly as a SAU-listed Medical - Care Facilities company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
79
days
Expected Date
Sep 2, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away79
Expected DateSep 2, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $0.93 | — | — | — | $0.95B | — |
| ▼ Q2 FY2026 | May 3, 2026 | $0.80 | $0.28 | -64.9% | $0.77B | $0.77B | -0.5% |
| — Q1 FY2026 | Feb 24, 2026 | $0.55 | $0.55 | +0.0% | $0.81B | $0.81B | +0.4% |
| ▼ Q4 FY2025 | Nov 2, 2025 | $0.77 | $0.44 | -43.0% | $0.77B | $0.81B | -5.5% |
| ▼ Q2 FY2025 | May 7, 2025 | $1.82 | $1.74 | -4.4% | $0.73B | $0.70B | +4.5% |
| ▲ Q1 FY2025 | Mar 2, 2025 | $0.69 | $1.16 | +68.1% | $0.75B | $0.79B | -4.9% |
| ▲ Q4 FY2024 | Nov 3, 2024 | $0.57 | $0.67 | +17.7% | $0.73B | $0.69B | +6.6% |
| — Q3 FY2024 | Aug 4, 2024 | — | $0.67 | — | $0.71B | $0.69B | +3.8% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$0.93
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 3, 2026Miss
EPS Actual
$0.28
EPS Est.
$0.80
EPS Surpr.
-64.9%
Revenue
$0.77B
Q1 FY2026
Feb 24, 2026
EPS Actual
$0.55
EPS Est.
$0.55
EPS Surpr.
+0.0%
Revenue
$0.81B
Q4 FY2025
Nov 2, 2025Miss
EPS Actual
$0.44
EPS Est.
$0.77
EPS Surpr.
-43.0%
Revenue
$0.77B
Q2 FY2025
May 7, 2025Miss
EPS Actual
$1.74
EPS Est.
$1.82
EPS Surpr.
-4.4%
Revenue
$0.73B
Q1 FY2025
Mar 2, 2025Beat
EPS Actual
$1.16
EPS Est.
$0.69
EPS Surpr.
+68.1%
Revenue
$0.75B
Q4 FY2024
Nov 3, 2024Beat
EPS Actual
$0.67
EPS Est.
$0.57
EPS Surpr.
+17.7%
Revenue
$0.73B
Q3 FY2024
Aug 4, 2024
EPS Actual
$0.67
EPS Est.
—
EPS Surpr.
—
Revenue
$0.71B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $0.93 | $0.93 | $0.93 | 1 |
| Q1 FY2026 | $0.80 | $0.80 | $0.80 | 1 |
| Q4 FY2025 | $0.55 | $0.55 | $0.55 | 1 |
| Q3 FY2025 | $0.77 | $0.77 | $0.77 | 1 |
| Q2 FY2025 | $0.69 | $0.69 | $0.69 | 1 |
| Q1 FY2025 | $1.82 | $1.82 | $1.82 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $1.0B | $1.0B | $1.0B | 1 |
| Q1 FY2026 | $0.8B | $0.8B | $0.8B | 2 |
| Q4 FY2025 | $0.8B | $0.8B | $0.8B | 3 |
| Q3 FY2025 | $0.8B | $0.8B | $0.8B | 3 |
| Q2 FY2025 | $0.7B | $0.8B | $0.8B | 4 |
| Q1 FY2025 | $0.7B | $0.7B | $0.7B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 3, 2026 | -64.9% | $36.92 | $37.48 | +1.52% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +0.0% | $33.04 | $32.68 | -1.09% |
| ▼ Q4 FY2025 | Nov 2, 2025 | -43.0% | $51.15 | $50.75 | -0.78% |
| ▼ Q2 FY2025 | May 7, 2025 | -4.4% | $71.20 | $70.70 | -0.70% |
| ▲ Q1 FY2025 | Mar 2, 2025 | +68.1% | $76.90 | $74.40 | -3.25% |
| ▲ Q4 FY2024 | Nov 3, 2024 | +17.7% | $72.30 | $71.40 | -1.24% |
| — Q3 FY2024 | Aug 4, 2024 | — | $77.40 | $75.00 | -3.10% |
| — Q2 FY2024 | May 5, 2024 | — | $91.00 | $90.00 | -1.10% |
Q2 FY2026+1.52%
Report Date
May 3, 2026
EPS Beat/Miss
-64.9%
Price Before
$36.92
Price After
$37.48
Q1 FY2026-1.09%
Report Date
Feb 24, 2026
EPS Beat/Miss
+0.0%
Price Before
$33.04
Price After
$32.68
Q4 FY2025-0.78%
Report Date
Nov 2, 2025
EPS Beat/Miss
-43.0%
Price Before
$51.15
Price After
$50.75
Q2 FY2025-0.70%
Report Date
May 7, 2025
EPS Beat/Miss
-4.4%
Price Before
$71.20
Price After
$70.70
Q1 FY2025-3.25%
Report Date
Mar 2, 2025
EPS Beat/Miss
+68.1%
Price Before
$76.90
Price After
$74.40
Q4 FY2024-1.24%
Report Date
Nov 3, 2024
EPS Beat/Miss
+17.7%
Price Before
$72.30
Price After
$71.40
Q3 FY2024-3.10%
Report Date
Aug 4, 2024
EPS Beat/Miss
—
Price Before
$77.40
Price After
$75.00
Q2 FY2024-1.10%
Report Date
May 5, 2024
EPS Beat/Miss
—
Price Before
$91.00
Price After
$90.00
Avg Beat Reaction-1.86%
Avg Miss Reaction+0.01%
Beat Rate3 / 8 quarters
Largest Move-3.25% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: 4009.SR ends December
Middle East Healthcare Company (4009.SR) most recently reported earnings on May 3, 2026 for Q2 FY2026, posting EPS of $0.28 — missing the analyst consensus of $0.80 by -64.9%. The next 4009.SR earnings date is expected around September 2, 2026.
Each quarter, investors track 4009.SR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. 4009.SR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
4009.SR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
4009.SR earnings · 5 questionsMiddle East Healthcare Company's next earnings report is expected around September 2, 2026. 4009.SR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; 4009.SR historically reports after market close (AMC).
4009.SR earnings datewhen is 4009.SR earnings4009.SR next earnings datewhen does 4009.SR report earnings4009.SR earnings calendar
▸ Source: FMP · Middle East Healthcare Company SEC filings · US GAAP · Middle East Healthcare Company SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026